Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
Portfolio Pulse from Vandana Singh
Incyte Corporation (NASDAQ: INCY) released promising topline results from its Phase 3 inMIND trial for Monjuvi (tafasitamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma. The trial met its primary and key secondary endpoints, showing no new safety signals. Incyte plans to file a supplemental marketing application by the end of the year.
August 16, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incyte Corporation released positive Phase 3 trial results for Monjuvi in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma. The trial met its primary and key secondary endpoints, showing no new safety signals. Incyte plans to file a supplemental marketing application by the end of the year.
The positive Phase 3 trial results and the plan to file for expanded FDA approval are likely to boost investor confidence in Incyte. The stock is already up 1.82% in premarket trading, indicating a positive short-term impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100